Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from pharmaphorum

11:30 EDT 25th September 2018 | BioPortfolio

Here are the most relevant search results for "pharmaphorum" found in our extensive news archives from over 250 global news sources.

More Information about pharmaphorum on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about pharmaphorum for you to read. Along with our medical data and news we also list pharmaphorum Clinical Trials, which are updated daily. BioPortfolio also has a large database of pharmaphorum Companies for you to search.

Showing News Articles 1–25 of 743 from pharmaphorum

Monday 24th September 2018

Roche aims to improve cancer treatments with DNA blood test

Roche has launched a blood test that can identify 70 of the most commonly mutated genes in solid tumours, as the company seeks to make more medicine more personalised. The test known as FoundationOne Liquid can identify circulating tumour DNA in t...

Public inquiry investigates thousands of deaths from infected NHS blood

A public inquiry has opened to look into how infected NHS blood killed more than 2,900 people since the 1970s. The Infected Blood Inquiry, headed up by Sir Brian Langstaff, a former high court judge, was announced in July last year following years...

Underinvestment in medtech threatens sector growth - EY

Underinvestment in medical technology could threaten growth in the sector, according to a report by Ernst & Young (EY). In its 2018 report on medical technology, Pulse of the industry, EY states that short-term growth is prioritised over long-...

Study shows AZ's Farxiga diabetes drug cuts heart risks

AstraZeneca’s Farxiga has become the latest type 2 diabetes drug to show it can reduce cardiovascular risk in a clinical trial. Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin) was the first diabetes drug to show an improvement in ca...

Novartis, Bayer consider appeal as court says Avastin can be used in AMD

England’s High Court has ruled it is lawful to use Roche’s Avastin (bevacizumab) in an unlicensed use in wet age-related macular degeneration (AMD) instead of more expensive approved drugs from Novartis and Bayer. While NHS organisations welcomed ...

Friday 21st September 2018

Bedrock, DDB and Insypher lead at PM Society Digital Awards 2018

Bedrock, DDB Remedy and Insypher each scored two Golds at last night’s PM Society Digital Awards 2018 in London. Bedrock picked up its prizes in the Congress, Meetings & Events and Corporate Communications categories, DDB Remedy won in Film an...

Spark/Novartis eye gene therapy nears EU market – but at what price?

Spark Therapeutics’ and Novartis Luxturna gene therapy for a rare inherited eye disease has been okayed by European regulators, paving the way for an EU licence in the coming months. A marketing authorisation from the European Commission is usuall...

EU regulators back Ipsen cancer drug in new liver cancer use

Ipsen’s bid to build a cancer franchise around its Cabometyx (cabozantinib) is gathering pace after European regulators backed it in a new indication of second line liver cancer – a use where BMS rival immunotherapy drug Opdivo has failed to gain tra...

MPs call for NHS funding for HIV prevention drug

Leading UK politicians have called for an HIV prevention drug to be made available across the NHS, after a court ruling paved the way for cheap generic versions of Gilead’s Truvada. Conservative MPs Crispin Blunt and Nigel Evans, and Labour’s Step...

Pharma body agrees five-year deal to boost NHS innovation

The UK’s pharma trade body, the Association of the British Pharmaceutical Industry (ABPI), has signed a five-year partnership that aims to increase the use of novel medical technology across the NHS. The partnership with the Academic Health Scienc...

Celgene passes on OncoMed cancer drug, biotech's shares tank

Celgene has decided against taking an option on Oncomed’s cancer drug navicixizumab, sending the California biotech’s shares into freefall. Following the announcement Oncomed’s value fell by nearly 14% on the Nasdaq following the news that Celgene...

Thursday 20th September 2018

UK public-private partnership to use AI to cut drug failure rate

A UK R&D project has secured a government grant to help its artificial intelligence (AI)-based drug discovery project. Government-backed agency Innovate UK is backing the  £1 million project, which is a collaboration between two small tech bus...

AZ expands role in China, to include robots and health tech

AstraZeneca is planning to expand its role as a drug supplier in China to becoming a wider provider of healthcare through its use of robotics and other tech. The pharma giant will use artificial intelligence (AI), robotics and digital applications...

Mylan and Fujifilm join Humira bunfight as fifth EU biosimilar approved

Mylan and Fujifilm Kyowa Kirin Biologics have got their Humira biosimilar approved in Europe – the fifth cut-price competitor approved ahead of patent expiry on AbbVie’s inflammatory diseases blockbuster next month. Already backed by Europe’s CHMP...

Pharma depriving developing countries of taxes - report

A damning report by Oxfam claims that pharma giants are ‘depriving’ developing countries of millions of dollars' worth of tax money annually. Oxfam’s report, Prescription for Poverty, slammed Johnson & Johnson, Pfizer, Merck Sharp & Dohme ...

AliveCor pledges to outdo Apple Watch with 6-lead ECG

Apple made headlines earlier this month with its announcement of a new watch with an FDA-approved electrocardiogram (ECG) reader to indicate the wearer’s cardiac health. But not to be outdone, AliveCor, which had previously produced a competing EC...

MS campaigner Trishna Bharadia scoops Woman of the Year award

Multiple sclerosis campaigner Trishna Bharadia has been named Woman of the Year at the 2018 Asian Achievers Awards during a glittering ceremony in London. The awards at the Grosvenor House hotel, Park Lane, celebrated outstanding British Asian tal...

Wednesday 19th September 2018

Sosei shares tank after safety issue with Alzheimer's drug

Allergan and Sosei’s experimental Alzheimer’s medicine has run into trouble – the companies have called a halt to trials after an unexpected toxicology finding in an animal study. Japan-based Sosei has a licence agreement with Allergan for HTL0018...

FDA rejects Pharming's Ruconest HAE label expansion

The FDA has rejected Pharming’s application to expand the licence of Ruconest, for a use as prophylaxis for patients with the serious rare disease hereditary angioedema (HAE). The FDA asked Pharming to carry out an additional trial in its Complete...

Novo Nordisk lays off 400 staff in R&D shake-up

Novo Nordisk is laying off 400 people in Denmark and China so it can overhaul its R&D and speed up the expansion and diversification of products for serious chronic diseases. It will build four new ‘transformational research units’ this year t...

Truvada ruling could allow cheap HIV prevention in the UK

Cheap copies of Gilead’s HIV drug Truvada, which can also be used to reduce the risk of people becoming infected, could be available in the UK following a court ruling. Truvada (tenofovir disoproxil+emtricitabine) is used as the backbone of many H...

NICE rejects Novartis' CAR-T in adult lymphoma

NICE has said Novartis’ CAR-T therapy Kymriah cannot be funded by the NHS in adults with an aggressive form of lymphoma, calling for further discussions to get the drug on to the market. The cost-effectiveness body has recently green-lighted Cance...

Tuesday 18th September 2018

NICE okays funding for Novartis skin cancer combo

The combination of the Novartis drugs dabrafenib and trametinib for patients with stage 3 skin cancer will be funded by the NHS in England and Wales after a recommendation from cost regulators. The National Institute for Clinical Excellence (NICE)...

Roche decision support tool matches patients to trials

Roche has launched two new decision support tools aimed at matching patients to the most appropriate clinical trial, and helping clinicians search for relevant medical literature. The two apps are available on Roche’s Navify Tumour Board tool – th...

AI test detects early signs of dementia

A pioneering artificial intelligence (AI) computer test can help detect whether individuals are in the early stages of dementia. Through a series of questions with an interactive on-screen avatar, a computer programme designed by researchers from ...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks